Vyxeos (daunorubicin and cytarabine)

pCPA File Number: 21588

Negotiation Status:

Concluded with an LOI

Indication(s):

For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Sponsor/Manufacturer:

Jazz Pharmaceuticals Canada Inc.

CADTH Project Number:

PC0237

pCPA Engagement Letter Issued:

2022-01-13

Negotiation Process Concluded:

2022-04-27